RNA is the Next Frontier in Molecular Diagnostics

BioSpace | October 27, 2026 Mammogen has announced a clinical research partnership with MammoLink, a specialized women's health imaging provider, to expand community access to innovative breast cancer detection technologies. Through this collaboration, MammoLink will participate in Mammogen's KATELYN-ERIN clinical trial, a prospective study involving approximately 2,600 women. The partnership will leverage MammoLink's mobile 3D mammography network across Florida to evaluate Mammogen's genTRU-breast™ blood-based RNA assay alongside traditional breast imaging. The initiative represents an important step toward integrating molecular diagnostics with community-based breast care, with the goal of improving accessibility and supporting earlier breast cancer detection, particularly for women with dense breast tissue. Click Here to Read the Full Article on BioSpace

23 October 2026 America's Small Business Network (ASBN) | October 23, 2026 Mammogen CEO and Co-Founder Liz Cormier-May was featured on ASBN's The Female Founder Show, discussing the company's mission to advance breast cancer detection through innovative RNA-based blood testing. During the interview, Cormier-May highlighted the challenges women with dense breast tissue face with traditional mammography and explained how Mammogen's genTRU-breast™ blood-based assay is being developed to provide additional information that could support earlier detection. Cormier-May also shared the personal experiences behind Mammogen's founding, the challenges of advancing innovation in women's health, and her advice for aspiring female entrepreneurs. Click Here to Read the Full Article and Watch the Interview →